Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC decreased its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 5.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 7,420 shares of the biopharmaceutical company’s stock after selling 391 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Intra-Cellular Therapies were worth $543,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in Intra-Cellular Therapies by 50.8% in the first quarter. SG Americas Securities LLC now owns 4,590 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 1,547 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Intra-Cellular Therapies by 9.8% in the 1st quarter. Sei Investments Co. now owns 128,311 shares of the biopharmaceutical company’s stock worth $8,880,000 after acquiring an additional 11,488 shares during the period. Headlands Technologies LLC bought a new stake in Intra-Cellular Therapies in the 1st quarter valued at about $32,000. Russell Investments Group Ltd. boosted its stake in Intra-Cellular Therapies by 232.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock valued at $3,519,000 after purchasing an additional 35,528 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 9.1% in the first quarter. ProShare Advisors LLC now owns 23,621 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 1,962 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 4.8 %

NASDAQ ITCI opened at $83.42 on Friday. The company has a 50 day moving average price of $78.07 and a two-hundred day moving average price of $74.21. Intra-Cellular Therapies, Inc. has a 12-month low of $54.17 and a 12-month high of $93.45. The stock has a market capitalization of $8.84 billion, a PE ratio of -95.88 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) EPS. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 28,680 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $79,696,697.34. This trade represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Insiders sold 179,471 shares of company stock worth $13,670,383 over the last ninety days. Company insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

ITCI has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Morgan Stanley increased their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Needham & Company LLC restated a “buy” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. Piper Sandler upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Finally, UBS Group lowered their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.